Own CSL shares? Here's a look at the biotech's balance sheet

CSL shares have lent investors strategic upside early in FY23.

| More on:
A man sitting at his dining table looks at his laptop and ponders the CSL balance sheet and the value of CSL shares today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have lifted in July to bring a bullish flavour to the new financial year
  • Investors have rallied the share more than 8% higher in July in almost vertical fashion
  • CSL has a book value per share of $32, according to its latest financial statement 

Shares in biotech giant CSL Limited (ASX: CSL) have rerated in FY23. In fact, they have now pushed just over 8% into the green since the start of the month.

That's ahead of the 6% return for the S&P/ASX 200 Health Care Index (ASX: XHJ) over the same period.

CSL shares finished the session on Tuesday at $290.66 — down 2.02% for the day.

Following the company's announcement of its acquisition of Vifor Pharma AG last year, current global supply chain headwinds, and (hopefully) a wind back in global COVID-19 cases, let's take a look at CSL's financial position and the book value of CSL shares.

CSL balance sheet

From its semi-annual report in December 2021, CSL reported cash & equivalents of $8.7 billion. Notably, some of this will have been allocated to the acquisition.

It had total assets of more than $32 billion, or around $24 billion minus the cash and marketable securities.

On this amount, it held debt of around $7.6 billion. The interest on this debt was covered more than 32 times from operating income.

This gives CSL a total debt ratio of around 24%. Its total capital base is financed at around 28% with debt.

Meanwhile, short-term obligations are covered 5 times from liquid assets, and around 3.4 times when separating CSL's inventory. This means it should meet its financial obligations as they come due.

As such, it had around $13.6 billion in working capital as at December 2021. That's up from $5.7 billion in the prior half.

Book value of CSL shares

With this, shareholders held equity of more than $19.3 billion in the biotech giant. That provides a book value per share of $32.

This year to date, CSL shares have fallen 1.8% but are up 1.46% over the past 12 months.

TradingView Chart

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »